Form 8-K - Current report:
SEC Accession No. 0001213900-24-107941
Filing Date
2024-12-11
Accepted
2024-12-11 17:02:28
Documents
15
Period of Report
2024-12-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea022443401-8k_denalicap.htm   iXBRL 8-K 30827
2 PRESS RELEASE, DATED DECEMBER 11, 2024 ea022443401ex99-1_denalicap.htm EX-99.1 4009
  Complete submission text file 0001213900-24-107941.txt   266152

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE decau-20241211.xsd EX-101.SCH 4225
4 XBRL DEFINITION FILE decau-20241211_def.xml EX-101.DEF 27341
5 XBRL LABEL FILE decau-20241211_lab.xml EX-101.LAB 37897
6 XBRL PRESENTATION FILE decau-20241211_pre.xml EX-101.PRE 25961
17 EXTRACTED XBRL INSTANCE DOCUMENT ea022443401-8k_denalicap_htm.xml XML 7488
Mailing Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022
Business Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022 6469785180
Denali Capital Acquisition Corp. (Filer) CIK: 0001913577 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41351 | Film No.: 241542286
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)